Skip to content
akaturk Academic measurement
Sign in Register

OpenAlex topic

Lung Cancer Research Studies

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,146 works 45 author topics

Works

2,146 works

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy Naive Patients With Advanced Stage Non Small Cell Lung Cancer 2008
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    PURPOSE: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS: This noninferiority, phase III, randomized study compared the overall…

  2. title Alectinib versus Crizotinib in Untreated iALK/i -Positive Non–Small-Cell Lung Cancer/title 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advance…

  3. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  5. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  6. Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study 2011
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    PURPOSE: This European Organisation for Research and Treatment of Cancer phase III trial assesses whether adjuvant whole-brain radiotherapy (WBRT) increases the duration of functional independence after surgery or radiosurgery of brain metastases. PATIENTS AND METHODS: Patients with one to three brain metastases of so…

  7. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer 1991
    OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer. We conducted a randomized clinical trial to test this…

  8. Ramucirumab plus docetaxel versus placebo plus docetaxel for second line treatment of stage IV non small cell lung cancer after disease progression on platinum based therapy REVEL a multicentre double blind randomised phase 3 trial 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  9. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study 2020
    OpenAlex top 1% OpenAlex 99.8%

    PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC. METHODS…

  10. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  11. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  12. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 2021
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

Academicians

45 academicians